FDA Clearance Tracker · K183313
EUROIMMUN Anti-tissue Transglutaminase ELISA (IgA), EUROIMMUN Anti-tissue Transglutaminase ELISA (IgG)
Last checked: Nov 20, 2026Latest source record: Feb 28, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Feb 28, 2019
Substantially Equivalent
Time to decision
91 days
Received Nov 29, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K183313
- Device name
- EUROIMMUN Anti-tissue Transglutaminase ELISA (IgA), EUROIMMUN Anti-tissue Transglutaminase ELISA (IgG)
- Applicant
- Euroimmun Us, Inc.
- Applicant location
- Mountain Lakes, NJ
- Received
- Nov 29, 2018
- Decided
- Feb 28, 2019
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.5660
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MVM. The earliest in FDA's data is K982366, decided Aug 27, 1998.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K183313
- The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Euroimmun Us, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K193115 · Decided Sep 17, 2020 · 310 days after receipt
Device type: Autoantibodies, Skin (Bullous Pemphigoid 180 And Bullous Pemphigoid 230 (OEG) · Laboratory Medicine & Pathology
- EUROIMMUN IFA Granulocyte Mosaic EUROPattern and EUROIMMUN EUROPLUS Granulocyte Mosaic EUROPattern510(k)
K172582 · Decided May 24, 2018 · 269 days after receipt
Device type: Test System, Antineutrophil Cytoplasmic Antibodies (Anca) (MOB) · Laboratory Medicine & Pathology
K172244 · Decided Apr 20, 2018 · 268 days after receipt
Device type: Anti-Dna Indirect Immunofluorescent Solid Phase (KTL) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.